These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16724185)

  • 1. Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.
    Andréen L; Sundström-Poromaa I; Bixo M; Nyberg S; Bäckström T
    Psychopharmacology (Berl); 2006 Aug; 187(2):209-21. PubMed ID: 16724185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone.
    Andréen L; Sundström-Poromaa I; Bixo M; Andersson A; Nyberg S; Bäckström T
    Psychoneuroendocrinology; 2005 Feb; 30(2):212-24. PubMed ID: 15471618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators.
    Andréen L; Nyberg S; Turkmen S; van Wingen G; Fernández G; Bäckström T
    Psychoneuroendocrinology; 2009 Sep; 34(8):1121-32. PubMed ID: 19272715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women.
    Wihlbäck AC; Nyberg S; Bäckström T; Bixo M; Sundström-Poromaa I
    Psychoneuroendocrinology; 2005 Jan; 30(1):38-50. PubMed ID: 15358441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels.
    Bernardi F; Pluchino N; Pieri M; Begliuomini S; Lenzi E; Puccetti S; Casarosa E; Luisi M; Genazzani AR
    Neuroendocrinology; 2006; 83(5-6):348-59. PubMed ID: 16931878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to a neurosteroid is increased during addition of progestagen to postmenopausal hormone replacement therapy.
    Wihlbäck AC; Sundström-Poromaa I; Nyberg S; Bäckström T
    Neuroendocrinology; 2001 Jun; 73(6):397-407. PubMed ID: 11408781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone.
    Andréen L; Spigset O; Andersson A; Nyberg S; Bäckström T
    Maturitas; 2006 Jun; 54(3):238-44. PubMed ID: 16406399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allopregnanolone serum concentrations and neurosteroid sensitivity during withdrawal from postmenopausal hormone therapy.
    Wihlbäck AC; Nyberg S; Andersson A; Bixo M; Bäckström T; Sundström-Poromaa I
    Gynecol Endocrinol; 2007 Oct; 23(10):590-6. PubMed ID: 17852417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopregnanolone and mood disorders.
    Bäckström T; Bixo M; Johansson M; Nyberg S; Ossewaarde L; Ragagnin G; Savic I; Strömberg J; Timby E; van Broekhoven F; van Wingen G
    Prog Neurobiol; 2014 Feb; 113():88-94. PubMed ID: 23978486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone.
    Klatzkin RR; Morrow AL; Light KC; Pedersen CA; Girdler SS
    Psychoneuroendocrinology; 2006 Nov; 31(10):1208-19. PubMed ID: 17046166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone effects during sequential hormone replacement therapy.
    Andréen L; Bixo M; Nyberg S; Sundström-Poromaa I; Bäckström T
    Eur J Endocrinol; 2003 May; 148(5):571-7. PubMed ID: 12720542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers.
    Freeman EW; Purdy RH; Coutifaris C; Rickels K; Paul SM
    Neuroendocrinology; 1993 Oct; 58(4):478-84. PubMed ID: 7904330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome.
    Nyberg S; Bäckström T; Zingmark E; Purdy RH; Poromaa IS
    Gynecol Endocrinol; 2007 May; 23(5):257-66. PubMed ID: 17558683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy.
    Björn I; Sundström-Poromaa I; Bixo M; Nyberg S; Bäckström G; Bäckström T
    J Clin Endocrinol Metab; 2003 May; 88(5):2026-30. PubMed ID: 12727949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of triazolam in women: relationships with progesterone, estradiol and allopregnanolone.
    de Wit H; Rukstalis M
    Psychopharmacology (Berl); 1997 Mar; 130(1):69-78. PubMed ID: 9089849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative mood changes during hormone replacement therapy: a comparison between two progestogens.
    Björn I; Bixo M; Nöjd KS; Nyberg S; Bäckström T
    Am J Obstet Gynecol; 2000 Dec; 183(6):1419-26. PubMed ID: 11120505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects.
    Schmidt PJ; Purdy RH; Moore PH; Paul SM; Rubinow DR
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1256-60. PubMed ID: 7962316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women.
    Bernardi F; Pieri M; Stomati M; Luisi S; Palumbo M; Pluchino N; Ceccarelli C; Genazzani AR
    Gynecol Endocrinol; 2003 Feb; 17(1):65-77. PubMed ID: 12724021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy.
    Björn I; Bixo M; Nöjd KS; Collberg P; Nyberg S; Sundström-Poromaa I; Bäckström T
    Gynecol Endocrinol; 2002 Feb; 16(1):1-8. PubMed ID: 11915576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.